福州宁丹榕康生物医药科技

Ningdan Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for central nervous system (CNS) disorders, particularly acute ischemic stroke. The company's lead candidate, Y-2, is a sublingual tablet combining edaravone and dexborneol, currently undergoing Phase 3 clinical trials to evaluate its efficacy in neuroprotection. Ningdan leverages its expertise in drug delivery and formulation to create treatments that offer improved patient convenience and clinical outcomes. With a focus on high-unmet-need areas in neurology, the company is advancing a robust pipeline of small molecule candidates. Ningdan operates as a key player in the Chinese biotech ecosystem with significant R&D activities in Nanjing and Fuzhou.